What's beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study.
HGSOC
androgen receptor
estrogen receptors
progesterone receptor
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Sep 2022
22 Sep 2022
Historique:
received:
01
09
2022
accepted:
17
09
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
15
10
2022
Statut:
epublish
Résumé
Several studies have explored the prognostic role of hormone receptor status in high-grade serous ovarian cancer (HGSOC) patients. However, few reports have investigated their expression according to BRCA mutational status. The aim of this single-center, observational, retrospective study was to explore the hormone receptor pattern and its potential prognostic role in a cohort of 207 HGSOC women stratified for BRCA mutational status. To this end, ERα, ERβ1, ERβ2, ERβ5, PR, and AR expression were assessed by immunohistochemistry in 135 BRCA-wild type (BRCA-wt) and 72 BRCA1/2 mutation carriers (BRCA-mut). No significant difference emerged in hormone receptor expression between the two sub-samples, except for a significantly lower ERα expression observed in pre-menopausal BRCA1/2-mut as compared to BRCA-wt patients (
Identifiants
pubmed: 36230510
pii: cancers14194588
doi: 10.3390/cancers14194588
pmc: PMC9559459
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Oncotarget. 2017 May 29;8(37):62400-62413
pubmed: 28977954
Stat Med. 2009 Aug 30;28(19):2473-89
pubmed: 19472308
Gynecol Oncol. 2018 Jul;150(1):158-165
pubmed: 29786517
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13162-7
pubmed: 16938840
Clin Cancer Res. 2009 Mar 1;15(5):1514-8
pubmed: 19223511
Semin Cancer Biol. 2021 Dec;77:144-166
pubmed: 34464704
Int J Cancer. 2000 Aug 1;87(3):317-21
pubmed: 10897034
Arch Pathol Lab Med. 2017 Oct;141(10):1402-1412
pubmed: 28714765
Cancers (Basel). 2020 Jun 22;12(6):
pubmed: 32580290
Science. 1999 May 21;284(5418):1354-6
pubmed: 10334989
Gynecol Oncol. 2014 Feb;132(2):351-9
pubmed: 24378878
Endocrine. 2005 Aug;27(3):227-38
pubmed: 16230778
Lancet Oncol. 2013 Aug;14(9):853-62
pubmed: 23845225
Hematol Oncol Clin North Am. 2018 Dec;32(6):997-1010
pubmed: 30390770
BMC Cancer. 2018 Oct 16;18(1):981
pubmed: 30326857
Endocr Relat Cancer. 2020 Feb;27(2):55-66
pubmed: 31778358
Sci Rep. 2016 May 03;6:25408
pubmed: 27139372
BMC Cancer. 2017 Aug 31;17(1):606
pubmed: 28859612
Histochem Cell Biol. 2019 Jan;151(1):91-96
pubmed: 30357509
J Mol Endocrinol. 2003 Feb;30(1):13-29
pubmed: 12580758
J Mol Endocrinol. 2015 Apr;54(2):R31-53
pubmed: 25587053
BMC Cancer. 2009 Sep 16;9:330
pubmed: 19758455
Endocr Relat Cancer. 2015 Dec;22(6):R339-63
pubmed: 26373571
J Clin Oncol. 2002 May 1;20(9):2310-8
pubmed: 11981002
Gynecol Oncol. 2011 Sep;122(3):573-9
pubmed: 21665249
Bioinformatics. 2018 Dec 1;34(23):4054-4063
pubmed: 29931226
Biosci Rep. 2021 May 28;41(5):
pubmed: 33891016
Endocrine. 2003 Nov;22(2):101-12
pubmed: 14665713
Curr Pharm Des. 2012;18(19):2734-57
pubmed: 22390760
Endocr Relat Cancer. 2005 Sep;12(3):533-48
pubmed: 16172191
Toxicol Sci. 2008 Oct;105(2):303-11
pubmed: 18644836
Front Endocrinol (Lausanne). 2014 Nov 12;5:192
pubmed: 25429284
Br J Cancer. 2002 Mar 18;86(6):879-85
pubmed: 11953818
Lancet Oncol. 2013 Nov;14(12):1226-32
pubmed: 24140203
Cells. 2019 Feb 19;8(2):
pubmed: 30791431
Gynecol Oncol. 2005 Apr;97(1):16-25
pubmed: 15790432
Cancers (Basel). 2018 Nov 12;10(11):
pubmed: 30424539
Cancers (Basel). 2021 Oct 06;13(19):
pubmed: 34638494